论文部分内容阅读
目的探讨研究并且进行仔细认真的比较使用速释片和格列吡嗪控释片治疗2型糖尿病所发生的一些不良反应以及对其血糖控制效果。方法将128例患有2型糖尿病患者随机分为速释片组以及格列吡嗪控释片组,其中素释片组67例,格列吡嗪控释片组61例,细心观察治疗14周后的胰岛素、血糖和C肽水平的状况、两组的药物不良反应情况以及所使用的维持剂量。结果两组治疗后空腹血糖和餐后2 h血糖全部都有降低的趋势,控释片组的降空腹血糖效果要比速释片组体现的更为显著(P<0.05);控释片组的维持剂量较小;两组不良反应发生率近乎相同。糖化血红蛋白治疗后均有下降,但组间比较差别不是很大;空腹胰岛素及C肽治疗前后两组均没有显著的不同。结论格列吡嗪控释片能够充分的发挥与速释片有所相同的治疗效果,其降空腹血糖效果相比会更好。
OBJECTIVE: To investigate and carefully compare the adverse effects of glycemic control and glycemic control on type 2 diabetes mellitus with immediate-release tablets and glipizide controlled-release tablets. Methods 128 patients with type 2 diabetes mellitus were randomly divided into immediate-release tablets and glipizide controlled-release tablets, of which 67 were in controlled-release tablets and 61 in controlled-release glipizide tablets. Careful observation and treatment of 14 Weeks after insulin, blood sugar and C-peptide levels, adverse drug reactions in both groups, and the maintenance dose used. Results Both fasting blood glucose and postprandial 2-h blood glucose tended to decrease in both groups. The fasting plasma glucose lowering effect of the controlled-release tablet group was more significant than that of the immediate-release tablet group (P <0.05) The maintenance dose is small; the incidence of adverse reactions in both groups is almost the same. Glycosylated hemoglobin decreased after treatment, but the difference between the groups is not large; fasting insulin and C peptide before and after treatment were no significant difference between the two groups. Conclusion Glipizide controlled-release tablets can fully exert the same therapeutic effect as immediate-release tablets, which will be better than the fasting glucose-lowering effect.